

PRESS RELEASE



September 28, 2018, Lund, Sweden

Increase in share capital and number of shares in Immunovia

The share capital and number of shares in Immunovia AB (publ) has changed due to share warrants being exercised in the company.

- The share capital has increased from SEK 974,042.65 to SEK 976,567.65.
- The number of shares has increased by 50,500 to 19,531,353 shares.
- The dilution amounts to 0.3%.

The share warrants that have been exercised are in part constituted of Immunovia's incentive program for senior management according to decisions taken at the 2015 and 2016 AGM's, issued the respective years.

This is information that Immunovia is obliged to make public pursuant to the Swedish Act on Trade in Financial Instruments. The information was submitted for publication, through the agency of the contact person set out above, at 08.30 CET on September 28, 2018.

For further information, please contact:

Mats Grahn

Chief Executive Officer, CEO, Immunovia

Tel.: +46-70-5320230

Email: mats.grahn@immunovia.com

About Immunovia

Immunovia AB was founded in 2007 by investigators from the Department of Immunotechnology at Lund University and CREATE Health, the Center for Translational Cancer Research in Lund, Sweden. Immunovia's strategy is to decipher the wealth of information in blood and translate it into clinically useful tools to diagnose complex diseases such as cancer, earlier and more accurately than previously possible. Immunovia's core technology platform, IMMray™, is based on antibody biomarker microarray analysis. The company is now performing clinical validation studies for the commercialization of IMMray™ PanCan-d that could be the first blood based test for early diagnosis of pancreatic cancer. In the beginning of 2016, the company started a program focused on autoimmune diseases diagnosis, prognosis and therapy monitoring. (Source: www.immunovia.com)

Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For more information, please visit www.immunovia.com.

###